Expression and clinical significance of Twist1 in bone marrow and extramedullary lesions tissues in patients with myeloma / 国际检验医学杂志

ABSTRACT

Objective To explore the expression and clinical significance of Twist1 in bone marrow and ex-tramedullary lesions of patients with myeloma.Methods 30 cases of patients diagnosed with multiple myelo-ma(MM)treated in our hospital were selected for the study,and other 25 cases patients with MM combined with extramedullary lesions(EMD)were selected as the combined group.The positive expression rate of Twist1 in myeloma nuclei was detected by immunohistochemistry in the MM and EMD tissues,and the ex-pressions of Twist1 were compared in patients with different tumor stages,and the relationship between Twist1 and clinical parameters(gender,age)was analyzed.Results Twist1 could be expressed in the nucleus and cytoplasm of marrow tissue and extramedullary tissue among myeloma patients,and the high expression rate in patients complicated with extramedullary lesions was higher than that in the cytoplasm(P<0.05),and the high expression rate in the nucleus and cytoplasm of extramedullary tissues was higher than that in the myeloma group(P<0.05).The Twist1 expression rate in the nucleus of myeloma tissues was increased with the increase of the stages,but there was no significant difference in the expression rate between the two groups(P>0.05).The relationship analysis of Twist1 expression in the nucleus of bone marrow tissues and the clinicopathological features showed that the high or low Twist 1 expression was not significantly correlated with the gender and age(P>0.05),but had a certain relationship with clinical stages,and was positively cor-related with the disease stages(r=0.316,P<0.05).Conclusion Twist1 is highly expressed in bone marrow of patients with myeloma,especially in the nucleus of extramedullary lesions tissue of patients with combined with extramedullary disease,and the high expression of Twist1 is correlated with pathological staging,and it can be used as one of the clinical indicators for poor prognosis of patients with myeloma.